Full-Life Technologies has secured $63.3 million in financing to enhance its radiopharmaceutical pipeline and manufacturing capabilities, including the establishment of a GMP facility in Belgium.

Information on the Target

Full-Life Technologies Limited is a fully integrated global radiotherapeutics company headquartered in Shanghai, China, with operations in Belgium and Germany. Since its inception in August 2021, Full-Life has focused on harnessing the full value chain of radiopharmaceutical research, development, production, and commercialization to deliver significant clinical impact to patients. The company aims to address critical challenges currently facing the radiopharmaceutical sector through its innovative research and development efforts.

Recently, Full-Life Technologies completed a $63.3 million financing round, which includes $47.3 million in Series B equity financing and $16 million in loan facilities. This funding will enhance its radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. To date, Full-Life has secured over $110 million in total funding.

Industry Overview in Belgium

Belgium has established itself as a prominent hub for the healthcare and biopharmaceutical industries, characterized by its commitment to innovation and robust research capabilities. The country is home to numerous biotechnology firms, leading ac